ROCHE-TDM4258g



A phase II, single-arm, open-label study of Trastuzumab-MCC-DM1 administered intravenously to patients with HER2-positive metastatic breast cancer who have progressed while receiving HER2-directed therapy
trastuzumab emtansine
TDM4258g
NCT00509769
metastatic breast cancer
Phase 2
 
January 2014